US 12,136,474 B2
System and method for automated dosage calculation and patient treatment life cycle for a transgender patient
Gino Tutera, Scottsdale, AZ (US); and Stephen Nunn, Mesa, AZ (US)
Assigned to The SottoPelle Group, LLC, Scottsdale, AZ (US)
Filed by The SottoPelle Group, LLC, Scottsdale, AZ (US)
Filed on Aug. 12, 2021, as Appl. No. 17/401,294.
Application 17/401,294 is a continuation in part of application No. 16/799,820, filed on Feb. 24, 2020, granted, now 11,798,659.
Application 16/799,820 is a continuation of application No. 15/125,529, granted, now 10,572,628, previously published as PCT/US2015/019963, filed on Mar. 11, 2015.
Claims priority of provisional application 61/951,415, filed on Mar. 11, 2014.
Prior Publication US 2021/0375405 A1, Dec. 2, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. G16H 10/20 (2018.01); G06Q 10/00 (2023.01); G16H 10/60 (2018.01); G16H 20/10 (2018.01); G16H 40/20 (2018.01); G16H 50/20 (2018.01); G16H 40/67 (2018.01); G16H 50/70 (2018.01)
CPC G16H 10/20 (2018.01) [G06Q 10/00 (2013.01); G16H 10/60 (2018.01); G16H 20/10 (2018.01); G16H 40/20 (2018.01); G16H 50/20 (2018.01); G16H 40/67 (2018.01); G16H 50/70 (2018.01)] 36 Claims
OG exemplary drawing
 
1. A computer-implemented method of providing a dosage and a transgender patient treatment lifecycle comprising:
receiving, by a computerized device comprising a processor, an input device, and a display screen, an input signal of a user indicating an input directed to a patient sex and a patient status, wherein the patient status is automatically determined by the processor and includes at least one of a new patient, a returning patient and a booster patient;
determining by the processor an effective estradiol dosage and an effective testosterone dosage using dosage calculation methods selected based on the patient status, automated male-to-female input parameters, and male-to-female tracking parameters in response to receiving an input indicating that the patient sex is male-to-female;
determining by the processor an effective testosterone dosage using dosage calculation methods selected based on the patient status, automated female-to-male input parameters, and female-to-male tracking parameters in response to receiving an input indicating that the patient sex is female-to-male;
displaying on the display screen, the determined effective dosages; and
administering a pellet comprising at least one of the determined effective dosages to the patient.